Stocktoria
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $6,000 at a -99916.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.911 |
| Retained earnings / assets | -9.039 |
| EBIT / assets | -0.787 |
| Equity / liabilities | 26.413 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | 4/9 | -1.04 | — | — |
| SRRK | Scholar Rock Holding Corp | 1/9 | -9.91 | — | -100% |
| SABS | SAB Biotherapeutics, Inc. | 3/9 | 6.9 | 21.9 | — |
| RVMD | Revolution Medicines, Inc. | 1/9 | -0.01 | — | — |
| PMCB | PharmaCyte Biotech, Inc. | 4/9 | 13.39 | — | — |
| PALI | PALISADE BIO, INC. | 3/9 | — | — | — |
| ELOX | Eloxx Pharmaceuticals, Inc. | 1/9 | — | — | — |
About CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
FAQ
Is CELZ financially healthy?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CELZ pay a dividend?
No, CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. does not currently pay a dividend.
How profitable is CELZ?
In FY2025, CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. had a net margin of -99916.8% and a return on equity of -79.7%.
What is the analyst price target for CELZ?
The average Wall-Street price target for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. is $20.00, about 1566.7% above the recent price, from 1 analysts.
Is CELZ a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.